Bronchodilator Responsiveness and Reported Respiratory Symptoms in an Adult Population

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Tan, Wan C ^a   Bourbeau, Jean ^b   Hernandez, Paul ^c   Chapman, Kenneth R ^d   Cowie, Robert ^e   FitzGerald, J Mark ^a   Aaron, Shawn ^f   Marciniuk, Darcy D ^g   Maltais, Francois ^h   Buist, A Sonia ⁱ   O'Donnell, Denis E ^j   Sin, Don D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF SASKATCHEWAN   (Canada)

^h LAVAL UNIVERSITY   (Canada)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j QUEEN S UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; SALBUTAMOL;

ADULT; ANTHROPOMETRY; ARTICLE; DRUG RESPONSE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY CONTROL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; RISK FACTOR; SMOKING; SPIROMETRY;

AGED; ASTHMA; BRONCHITIS, CHRONIC; BRONCHODILATOR AGENTS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RISK FACTORS; SMOKING; SPIROMETRY; VITAL CAPACITY;

EID: 84875008769     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058932     Document Type: Article

References (28)

1. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, et al. (2005) Interpretative strategies for lung function tests. Eur Respir J 26: 948-968.
2. Hanania NA, B RC, Donohue JF, Martin UJ, (2011) Bronchodilator Reversibility in COPD. Chest 140: 1055-1063.
3. Van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ, (2002) Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 324: 1370.
4. Hansen EF, Vestbo J, (2005) Bronchodilator reversibility in COPD: the roguish but harmless little brother of airway hyperresponsiveness? Eur Respir J 26: 6-7.
5. Lehmann S, Vollset SE, Nygaard HA, Gulsvik A, (2004) Factors determining performance of bronchodilator reversibility tests in middle-aged and elderly. Respir Med 98: 1071-1079.
6. Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koeter GH, et al. (1992) Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax 47: 429-436.
7. Eliasson O, Degraff AC Jr, (1985) The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables. Am Rev Respir Dis 132: 858-864.
8. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, et al. (2011) Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 365: 1184-1192.
9. Dales RE, Spitzer WO, Tousignant P, Schechter M, Suissa S, (1988) Clinical interpretation of airway response to a bronchodilator. Epidemiologic considerations. Am Rev Respir Dis 138: 317-320.
10. Lehmann S, Bakke PS, Eide GE, Gulsvik A, (2007) Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. Respir Med 101: 1183-1190.
11. Tan WC, Vollmer WM, Lamprecht B, Mannino DM, Jithoo A, et al. (2012) Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax 67: 718-726.
12. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, et al. (2008) Bronchodilator responsiveness in patients with COPD. Eur Respir J 31: 742-750.
13. Walker PP, Calverley PM, (2008) The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. COPD 5: 147-152.
14. Cerveri I, Pellegrino R, Dore R, Corsico A, Fulgoni P, et al. (2000) Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 88: 1989-1995.
15. Ramsdell JW, Tisi GM, (1979) Determination of bronchodilation in the clinical pulmonary function laboratory. Role of changes in static lung volumes. Chest 76: 622-628.
16. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, et al. (2007) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370: 741-750.
17. Tan WC, Bourbeau J, FitzGerald JM, Cowie R, Chapman K, et al. (2011) Can age and sex explain the variation in COPD rates across large urban cities? A population study in Canada. Int J Tuberc Lung Dis 15: 1691-1698.
18. Methvin JN, Mannino DM, Casey BR, (2009) COPD prevalence in southeastern Kentucky: the burden of lung disease study. Chest 135: 102-107.
19. Anon (1995) Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 152: 1107-1136.
20. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, et al. (1993) Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 16: 5-40.
21. Kainu A, Lindqvist A, Sarna S, Lundback B, Sovijarvi A, (2008) FEV1 response to bronchodilation in an adult urban population. Chest 134: 387-393.
22. Sourk RL, Nugent KM, (1983) Bronchodilator testing: confidence intervals derived from placebo inhalations. Am Rev Respir Dis 128: 153-157.
23. Ben Saad H, Prefaut C, Tabka Z, Zbidi A, Hayot M, (2008) The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther 21: 767-773.
24. Newton MF, O'Donnell DE, Forkert L, (2002) Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 121: 1042-1050.
25. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, et al. (2000) Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 16: 269-275.
26. O'Donnell DE, Lam M, Webb KA, (1998) Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158: 1557-1565.
27. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, et al. (2003) Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 21: 86-94.
28. Hyatt RE, Cowl CT, Bjoraker JA, Scanlon PD, (2009) Conditions associated with an abnormal nonspecific pattern of pulmonary function tests. Chest 135: 419-424.